Get to know our clinical trials
Phase 1, open-label, 3-part clinical trial to evaluate potential drug-drug interactions involving enzomenib (DSP-5336), as well as the impact of moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of enzomenib
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE 1, OPEN-LABEL, 3-PART STUDY TO EVALUATE POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING ENZOMENIB (DSP-5336), AS WELL AS THE IMPACT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ENZOMENIB IN ADULT PATIENTS WITH ADVANCED CANCER
- Code EudraCT: 2025-524652-63-00
- Protocol number: DSP-5336-103
- Promoter: Sumitomo Pharma America
- Molecule/Drug: DSP-5336
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.